Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Sight Sciences, Inc. is a U.S.-based medical device company focused on developing and commercializing interventional technologies for the treatment of eye diseases. The company operates primarily within the ophthalmology and medical devices industries, with a strategic emphasis on glaucoma and dry eye disease—two of the most prevalent chronic eye conditions. Sight Sciences’ core value proposition centers on tissue-preserving, non-implant-based procedures intended to be performed earlier in the disease continuum than traditional surgical approaches.
The company’s primary revenue drivers are its proprietary device platforms used by ophthalmologists and optometrists in clinical and surgical settings. Sight Sciences positions itself as a differentiated player by focusing on procedures that aim to restore natural physiological function rather than relying on permanent implants. Founded in 2011, the company advanced through private venture backing before completing an initial public offering in 2021, which supported expanded commercialization and clinical adoption of its product portfolio.
Business Operations
Sight Sciences operates through two primary business segments: Surgical Glaucoma and Dry Eye. The Surgical Glaucoma segment is anchored by the OMNI Surgical System, a minimally invasive device designed to treat open-angle glaucoma by addressing the eye’s natural outflow pathways. The Dry Eye segment is led by the TearCare System, which is used to treat evaporative dry eye disease by applying controlled heat therapy to the eyelids.
The company generates revenue primarily through the sale of disposable procedure kits and reusable capital equipment associated with these systems. Operations are predominantly domestic, with the United States accounting for the majority of revenue, while international sales are conducted through a combination of direct sales efforts and third-party distributors. Sight Sciences controls its core technologies internally and does not rely on significant joint ventures; publicly disclosed subsidiaries are limited and primarily support sales and distribution functions.
Strategic Position & Investments
Sight Sciences’ strategic direction emphasizes expanding adoption of interventional ophthalmic procedures earlier in the treatment cycle, particularly as alternatives to pharmaceutical therapy or more invasive surgery. Growth initiatives include increasing surgeon and clinician adoption, expanding clinical evidence to support broader use, and pursuing regulatory approvals and reimbursement coverage to support market penetration.
The company has historically focused on internal research and development rather than large-scale acquisitions, and no transformative acquisitions have been publicly disclosed as of recent filings. Investment priorities include continued enhancement of its existing platforms and exploration of adjacent interventional eye care applications. While emerging technologies are evaluated internally, publicly available information does not confirm material investments outside the company’s current glaucoma and dry eye focus areas.
Geographic Footprint
Sight Sciences is headquartered in the United States, with its principal executive offices located in California. The company’s commercial footprint is strongest in North America, where it maintains a direct sales force targeting ophthalmologists, glaucoma specialists, and optometrists.
Internationally, Sight Sciences has a presence in select markets across Europe, Asia-Pacific, and other regions through distributor relationships and limited direct operations. While international revenue represents a smaller portion of total sales compared to the U.S. market, global expansion remains a stated long-term objective, subject to regulatory approvals and market access considerations in each region.
Leadership & Governance
Sight Sciences was co-founded by industry professionals with prior experience in ophthalmic medical devices, and the company continues to be led by its founding executive team. Leadership emphasizes innovation in interventional care, disciplined capital allocation, and clinical evidence generation to support long-term growth.
Key members of the executive leadership team include:
- Scott Flora – Co-Founder and Chief Executive Officer
- Randall Waldrop – Co-Founder and President
- Tom Burns – Chief Financial Officer
- Alison Bauerlein – Chief Legal and Compliance Officer
- David Bade – Chief Technology Officer
The company operates under a board-governed structure consistent with U.S. public company standards, with oversight of strategy, risk management, and executive compensation.